Nkarta Announces February and March 2021 Investor Conference Schedule
Nkarta, Inc. (Nasdaq: NKTX) has announced its participation in several upcoming investor conferences, highlighting its focus on advancing NK cell therapies for cancer treatment.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Nkarta, Inc. (Nasdaq: NKTX) has announced its participation in several upcoming investor conferences, highlighting its focus on advancing NK cell therapies for cancer treatment. The events include the SVB Leerink 10th Annual Global Healthcare Conference on February 26, 2021, featuring a fireside chat at 1:40 p.m. ET, and the Cowen 41st Annual Health Care Conference on March 3-4, 2021, with no presentation scheduled. Additionally, Nkarta will present at the Barclays Global Healthcare Conference on March 11, 2021, at 10:20 a.m. ET. Live webcasts of these presentations will be available on their website.
Details
News Market Reaction – NKTX
The recorded move for NKTX in the trading session of this news was -2.25%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced its participation at these upcoming investor conferences:
| SVB Leerink 10th Annual Global Healthcare Conference February 26, 2021 Fireside chat presentation: 1:40 p.m. ET Cowen 41st Annual Health Care Conference March 3-4, 2021 No presentation Barclays Global Healthcare Conference March 11, 2021 Fireside chat presentation: 10:20 a.m. ET |
Live audio webcasts of the presentations will be available on the Investors section of Nkarta’s website, www.nkartatx.com. Replays of the webcasts will be archived on the website for approximately four weeks.
About Nkarta
Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies for cancer. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies, Nkarta is building a pipeline of cell therapy candidates generated by efficient manufacturing processes, which are engineered to enhance tumor targeting and improve persistence for sustained activity in the body. For more information, please visit the company’s website at www.nkartatx.com.
Nkarta Media/Investor Contact:
Greg Mann
Nkarta, Inc.
gmann@nkartatx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.